Edition:
India

Enlivex Therapeutics Ltd (ENLV.OQ)

ENLV.OQ on NASDAQ Stock Exchange Capital Market

9.19USD
17 Oct 2019
Change (% chg)

$0.62 (+7.23%)
Prev Close
$8.57
Open
$8.53
Day's High
$9.25
Day's Low
$8.11
Volume
26,999
Avg. Vol
12,330
52-wk High
$44.90
52-wk Low
$6.32

Latest Key Developments (Source: Significant Developments)

Enlivex Therapeutics Files For Resale Of 682,631 Ordinary Shares Of Co
Friday, 28 Jun 2019 

June 28 (Reuters) - Enlivex Therapeutics Ltd ::ENLIVEX THERAPEUTICS FILES FOR RESALE OF 682,631 ORDINARY SHARES OF CO BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Enlivex Therapeutics Provides Clinical Update On Positive Safety Profile Of Its Off-The-Shelf Cell Therapy Product In First Three Severe Sepsis Patients
Thursday, 6 Jun 2019 

June 6 (Reuters) - Enlivex Therapeutics Ltd ::ENLIVEX THERAPEUTICS PROVIDES CLINICAL UPDATE ON POSITIVE SAFETY PROFILE OF ITS OFF-THE-SHELF CELL THERAPY PRODUCT IN FIRST THREE SEVERE SEPSIS PATIENTS.ENLIVEX THERAPEUTICS LTD - OBTAINED REGULATORY APPROVAL FOR CONTINUED RECRUITMENT OF PATIENTS INTO PHASE IB CLINICAL TRIAL.ENLIVEX THERAPEUTICS LTD - THREE PATIENTS IN PHASE IB CLINICAL TRIAL OF OTS ALLOCETRA HAD SEVERE SEPSIS AT TIME OF OTS ALLOCETRA INFUSION.ENLIVEX THERAPEUTICS LTD - ALL THREE PATIENTS TOLERATED INFUSION WITHOUT SERIOUS ADVERSE EVENTS.ENLIVEX THERAPEUTICS LTD - ALL THREE PATIENTS DEMONSTRATED SWIFT CLINICAL IMPROVEMENT AFTER ADMINISTRATION OF BOTH STANDARD-OF-CARE AND OTS ALLOCETRA.ENLIVEX THERAPEUTICS LTD - ONGOING PHASE IB CLINICAL TRIAL IS EXPECTED TO RECRUIT UP TO 10 SEPSIS PATIENTS.  Full Article

Enlivex Therapeutics Ltd Announced Its Nasdaq Listing Under Symbol "ENLV"
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Bioblast Pharma Ltd ::IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS ANNOUNCES NASDAQ LISTING UNDER SYMBOL “ENLV” AND CLOSING OF PRIVATE PLACEMENT OF ORDINARY SHARES PRICED AT $12.25 PER SHARE.ENLIVEX THERAPEUTICS LTD - ANNOUNCED ITS NASDAQ LISTING UNDER SYMBOL "ENLV".  Full Article

Bioblast Pharma Reports Sale Of Its Trehalose Clinical Development Programs To Seelos Therapeutics
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Bioblast Pharma Ltd ::BIOBLAST PHARMA ANNOUNCES SALE OF ITS TREHALOSE CLINICAL DEVELOPMENT PROGRAMS TO SEELOS THERAPEUTICS.BIOBLAST PHARMA LTD - UNCONDITIONAL PAYMENT OF $3.5 MILLION.BIOBLAST PHARMA LTD - CONTINGENT PAYMENT OF UP TO ADDITIONAL $17 MILLION PLUS ROYALTIES FROM DEAL.BIOBLAST PHARMA LTD - SEELOS TO RECEIVE RIGHTS ALSO TO TREHALOSE FOR SANFILIPPO SYNDROME PROGRAM.  Full Article

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article